Galapagos NV

Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

12 Feb 2025 15:01:00 By Nasdaq GlobeNewswire

Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

08 Jan 2025 00:30:00 By Nasdaq GlobeNewswire

Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

07 Jan 2025 15:01:00 By Nasdaq GlobeNewswire

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

07 Dec 2024 11:30:00 By Nasdaq GlobeNewswire

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

05 Nov 2024 15:01:00 By Nasdaq GlobeNewswire

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

30 Oct 2024 15:01:00 By Nasdaq GlobeNewswire

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

06 Oct 2024 23:59:59 By Nasdaq GlobeNewswire

Galapagos receives transparency notification from EcoR1 Capital

30 Sep 2024 15:01:00 By Nasdaq GlobeNewswire

Galapagos receives transparency notification from EcoR1 Capital

16 Sep 2024 15:01:00 By Nasdaq GlobeNewswire

Galapagos receives transparency notification from FMR LLC

03 Sep 2024 15:01:00 By Nasdaq GlobeNewswire

Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma

23 Aug 2024 00:00:00 By Nasdaq GlobeNewswire

Galapagos receives transparency notification from FMR LLC

20 Aug 2024 15:01:00 By Nasdaq GlobeNewswire

Galapagos reports half-year 2024 financial results and provides second quarter business update

01 Aug 2024 15:01:00 By Nasdaq GlobeNewswire

Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

14 Jun 2024 15:01:00 By Nasdaq GlobeNewswire

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

30 May 2024 15:01:00 By Nasdaq GlobeNewswire

Galapagos creates new subscription right plans

16 May 2024 15:01:00 By Nasdaq GlobeNewswire

Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.

15 May 2024 15:01:00 By Nasdaq GlobeNewswire

Galapagos reports first quarter 2024 financial results  

02 May 2024 15:01:00 By Nasdaq GlobeNewswire

Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024

30 Apr 2024 15:01:00 By Nasdaq GlobeNewswire

Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024

04 Apr 2024 15:01:00 By Nasdaq GlobeNewswire